Denise Scots-knight - Net Worth and Insider Trading
Denise Scots-knight Net Worth
The estimated net worth of Denise Scots-knight is at least $5 Million dollars as of 2024-09-24. Denise Scots-knight is the CEO of Mereo BioPharma Group PLC and owns about 808,921 shares of Mereo BioPharma Group PLC (MREO) stock worth over $3 Million. Denise Scots-knight is also the Director of OncoMed Pharmaceuticals Inc and owns about 1,964,915 shares of OncoMed Pharmaceuticals Inc (OMED) stock worth over $2 Million. Details can be seen in Denise Scots-knight's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Denise Scots-knight has not made any transactions after 2024-09-13 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Denise Scots-knight
Denise Scots-knight Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Denise Scots-knight owns 3 companies in total, including Elanco Animal Health Inc (ELAN) , OncoMed Pharmaceuticals Inc (OMED) , and Albireo Pharma Inc (ALBO) .
Click here to see the complete history of Denise Scots-knight’s form 4 insider trades.
Insider Ownership Summary of Denise Scots-knight
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| ELAN | Elanco Animal Health Inc | 2019-03-11 | director |
| OMED | OncoMed Pharmaceuticals Inc | 2018-06-22 | director |
| ALBO | Albireo Pharma Inc | 2016-11-03 | director & 10 percent owner |
Denise Scots-knight Latest Holdings Summary
Denise Scots-knight currently owns a total of 2 stocks. Among these stocks, Denise Scots-knight owns 808,921 shares of Mereo BioPharma Group PLC (MREO) as of September 13, 2024, with a value of $3 Million and a weighting of 65.2%. Denise Scots-knight also owns 1,964,915 shares of OncoMed Pharmaceuticals Inc (OMED) as of December 19, 2014, with a value of $2 Million and a weighting of 34.8%.
Latest Holdings of Denise Scots-knight
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| MREO | Mereo BioPharma Group PLC | 2024-09-13 | 808,921 | 4.05 | 3,276,130 |
| OMED | OncoMed Pharmaceuticals Inc | 2014-12-19 | 1,964,915 | 0.89 | 1,748,774 |
Holding Weightings of Denise Scots-knight
Denise Scots-knight Form 4 Trading Tracker
According to the SEC Form 4 filings, Denise Scots-knight has made a total of 2 transactions in Mereo BioPharma Group PLC (MREO) over the past 5 years, including 0 buys and 2 sells. The most-recent trade in Mereo BioPharma Group PLC is the sale of 88,657 shares on September 13, 2024, which brought Denise Scots-knight around $381,225.
According to the SEC Form 4 filings, Denise Scots-knight has made a total of 0 transactions in OncoMed Pharmaceuticals Inc (OMED) over the past 5 years. The most-recent trade in OncoMed Pharmaceuticals Inc is the sale of 20,654 shares on December 19, 2014, which brought Denise Scots-knight around $448,398.
Insider Trading History of Denise Scots-knight
- 1
Denise Scots-knight Trading Performance
GuruFocus tracks the stock performance after each of Denise Scots-knight's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Denise Scots-knight is -41.88%. GuruFocus also compares Denise Scots-knight's trading performance to market benchmark return within the same time period. The performance of stocks bought by Denise Scots-knight within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Denise Scots-knight's insider trading performs compared to the benchmark.
Performance of Denise Scots-knight
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | -36.99 | | | | | |
| Relative Return to S&P 500(%) | -35.28 | | | | | |
Denise Scots-knight Ownership Network
Denise Scots-knight Owned Company Details
What does Elanco Animal Health Inc do?
Who are the key executives at Elanco Animal Health Inc?
Denise Scots-knight is the director of Elanco Animal Health Inc. Other key executives at Elanco Animal Health Inc include director & Pres. & Chief Executive Officer Jeffrey N Simmons , EVP & MANUFACTURING AND QUALITY Grace Mcardle , and See remarks Timothy J Bettington .
Elanco Animal Health Inc (ELAN) Insider Trades Summary
Over the past 18 months, Denise Scots-knight made no insider transaction in Elanco Animal Health Inc (ELAN). Other recent insider transactions involving Elanco Animal Health Inc (ELAN) include a net purchase of 30,000 shares made by William F Doyle , a net purchase of 6,600 shares made by Michael J Harrington , and a net purchase of 100,000 shares made by Jeffrey N Simmons .
In summary, during the past 3 months, insiders sold 0 shares of Elanco Animal Health Inc (ELAN) in total and bought 103,500 shares, with a net purchase of 103,500 shares. During the past 18 months, 0 shares of Elanco Animal Health Inc (ELAN) were sold and 156,600 shares were bought by its insiders, resulting in a net purchase of 156,600 shares.
Elanco Animal Health Inc (ELAN)'s detailed insider trading history can be found in Insider Trading Tracker table.
Elanco Animal Health Inc Insider Transactions
Denise Scots-knight Mailing Address
Above is the net worth, insider trading, and ownership report for Denise Scots-knight. You might contact Denise Scots-knight via mailing address: C/o Idenix Pharmaceuticals, Inc., 60 Hampshire Street, Cambridge Ma 02139.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
